Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease 2024-09-03 15:18
Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum's Disease 2024-03-04 16:22
Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction 2024-01-23 21:12
Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction 2024-01-23 18:35
Caliway to Present CBL-514 Phase 2 Study Results for Subcutaneous Fat Reduction at IMCAS 2024 2023-12-27 11:49
Caliway Closes Oversubscribed Capital Raise and Secures Over $100M to Advance CBL-514 Pivotal Phase 3 Study in Subcutaneous Fat Reduction 2023-12-16 15:47
Caliway Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite 2023-06-28 18:30
1